Clinical Trial Update: Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on tislelizumab in combination with BCG for high-risk non-muscle invasive bladder cancer (HR-NMIBC) across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Neoplasms
• Urogenital Neoplasms
• Urologic Neoplasms

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RenJi Hospital | Conditions: Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN